Upamostat hydrogen sulfate

Overview

Upamostat (WX-671) hydrogen sulfate, a prodrug of WX-UK1 ( HY-100415 ), is an orally active serine protease inhibitor . Upamostat hydrogen sulfate inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat hydrogen sulfate can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .

Application

Products | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PAI-1 | Products > Signaling Pathways > Ser/Thr Protease

Product Information

• Catalog No.: HY-16512
• CAS No.: 798560-68-6
• Molecular Formula: C64H96N10O16S3
• Molecular Weight: 1357.70
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source